Epizyme Inc Cmn Stk (EPZM) 10.44 $EPZM
Epizyme Teams Up with Roche's Genentech for Tazemetostat
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:32AM CDT
Epizyme (EPZM) announced that it has entered into a collaboration agreement with Roche's (RHHBY) Genentech to evaluate tazemetostat, in combination Tecentriq.
ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), EPZM: 10.44 (-0.28)
Epizyme Initiates Collaboration on Combination Trial of Tazemetostat and Tecentriq(TM) (atezolizumab) for Treatment of Non-Hodgkin Lymphoma
BusinessWire - Wed Jun 22, 11:09AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today it has entered into a collaboration agreement with Genentech, a member of the Roche Group, to conduct a clinical trial to investigate the anti-cancer effects of Epizyme's EZH2 inhibitor, tazemetostat, and Genentech's recently approved anti-PD-L1 cancer immunotherapy, Tecentriq(TM) (atezolizumab), when used in combination. The study will evaluate this combination regimen for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
EPZM: 10.44 (-0.28)
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 2:05PM CDT
Epizyme, Inc. (EPZM) reported encouraging preliminary data from its ongoing, global phase II trial on lead pipeline candidate, tazemetostat, at the American Society of Hematology Meeting on Lymphoma Biology.
ABT: 39.63 (+0.89), PFE: 34.59 (+0.12), EPZM: 10.44 (-0.28), BMY: 72.64 (+0.33)
Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting
BusinessWire - Sun Jun 19, 6:53AM CDT
--Four of five cohorts have now surpassed futility, including follicular lymphoma with EZH2 mutation; responses observed in all patient cohorts
EPZM: 10.44 (-0.28)
Earnings Estimates Moving Higher for Epizyme (EPZM): Time to Buy?
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:56AM CDT
Epizyme (EPZM) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
EPZM: 10.44 (-0.28)
Ardelyx Appoints Robert Bazemore to Its Board of Directors
PR Newswire - Tue Jun 07, 8:00AM CDT
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Robert Bazemore joined the Company's Board of Directors. Mr. Bazemore, who currently serves as President and Chief Executive Officer of Epizyme, Inc., brings with him broad experience in drug development and in navigating the challenges associated with preparing growing organizations for commercialization. Following the appointment of Mr. Bazemore to its Board of Directors, Ardelyx will have six independent board members.
EPZM: 10.44 (-0.28), ARDX: 8.27 (+0.39)
Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
Ekta Bagri - Zacks Investment Research - Tue May 10, 1:29PM CDT
Epizyme, Inc. (EPZM) reported a loss of 41 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 47 cents and the year-ago loss of $1.75.
SHPG: 180.29 (+4.91), EPZM: 10.44 (-0.28), GSK: 42.56 (+0.80), CELG: 100.66 (+1.43)
Epizyme (EPZM) Posts Narrower-Than-Expected Loss in Q1
Ekta Bagri - Zacks Investment Research - Mon May 09, 9:15AM CDT
Epizyme posted narrower-than-expected loss in the first quarter of 2016.
EPZM: 10.44 (-0.28)
Epizyme reports 1Q loss
Automated Insights - Mon May 09, 5:46AM CDT
CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Monday reported a loss of $22.9 million in its first quarter.
EPZM: 10.44 (-0.28)
Epizyme Announces First Quarter 2016 Financial Results and Provides Update on Execution Against Multi-Year Company Vision
BusinessWire - Mon May 09, 5:40AM CDT
--Conference call to be held today at 8:00 a.m. Eastern Time
EPZM: 10.44 (-0.28)
Epizyme Announces Collaboration with Lymphoma Study Association to Evaluate Combination of Tazemetostat with R-CHOP in Front-line Non-Hodgkin Lymphoma
BusinessWire - Mon May 09, 5:35AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has entered into a collaboration agreement with the Lymphoma Study Association (LYSA) to investigate the combination of tazemetostat with R-CHOP as a front-line treatment in patients with diffuse large B-cell lymphoma (DLBCL). LYSA is a premier cooperative group in France dedicated to clinical and translational research for lymphoma, and is certified by the French National Cancer Institute. Under the agreement, the phase 1b/2 trial will be jointly conducted with the Lymphoma Academic Research Organisation (LYSARC), the operational arm of LYSA.
EPZM: 10.44 (-0.28)
Epizyme Continues to Build Senior Leadership Team with Appointment of Matthew Ros as Chief Operating Officer
BusinessWire - Fri May 06, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as Chief Operating Officer. In this role, Mr. Ros will be responsible for directing and operationalizing Epizyme's launch readiness efforts for tazemetostat, and will report to Epizyme's President and Chief Executive Officer, Robert Bazemore.
EPZM: 10.44 (-0.28)
Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Mesothelioma
BusinessWire - Wed May 04, 5:35AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for tazemetostat for the treatment of adults with mesothelioma characterized by BAP1 loss-of-function. In the third quarter of this year, the company plans to initiate a phase 2 study in patients with mesothelioma.
EPZM: 10.44 (-0.28)
Epizyme to Report First Quarter 2016 Financial Results and Provide Corporate Update on May 9, 2016 and to Participate in Upcoming May Conferences
BusinessWire - Mon May 02, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today that management will host a conference call and live audio webcast on Monday, May 9, 2016, at 8:00 a.m. Eastern Time to report first quarter 2016 financial results and provide a corporate update. In addition, the company will be participating in two investor conferences in the month of May, Bank of America Merrill Lynch 2016 Health Care Conference and the UBS Global Health Care Conference.
EPZM: 10.44 (-0.28)
Epizyme Broadens Executive Leadership Team with Experienced New Officer and Senior Management
BusinessWire - Mon Apr 25, 7:00AM CDT
--Jeannie Chu joined as Vice President of Program and Portfolio Management
EPZM: 10.44 (-0.28)
Epizyme (EPZM) Q1 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 5:57PM CDT
Epizyme, Inc. (EPZM) is expected to report first-quarter 2016 results on Apr 26.
GILD: 83.37 (+0.92), EPZM: 10.44 (-0.28), SNY: 41.19 (+0.90), CELG: 100.66 (+1.43)
Epizyme Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer Research Annual Meeting 2016
BusinessWire - Mon Apr 18, 8:01AM CDT
--Data demonstrate that tazemetostat is only a weak inducer of CYP3A-mediated metabolism
EPZM: 10.44 (-0.28)
The Zacks Analyst Blog Highlights: CEMEX S.A.B. de C.V., Westmoreland Coal, Calpine, Epizyme and Edison International
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: CEMEX S.A.B. de C.V., Westmoreland Coal, Calpine, Epizyme and Edison International
CX: 6.80 (+0.28), CPN: 14.18 (+0.39), WLB: 9.69 (+0.54), EPZM: 10.44 (-0.28), EIX: 73.99 (+0.15)
Potential Winners: 3 Small-Cap Stocks Surging this Week
Zacks Premium Research - Zacks Investment Research - Wed Apr 06, 1:59PM CDT
These companies' shares are up by over 10% in the last week, so you may not want to miss out on what these corporations have to offer.
PRMW: 10.89 (+0.16), VTAE: 10.54 (+0.15), EPZM: 10.44 (-0.28)
5 Top-Ranked Stocks to Buy Before Earnings Release in April
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:22AM CDT
In spite of all the hiccups in Q1, we have cherry picked stocks with the help of our screening methodology that have been able to bear the turmoil.
CX: 6.80 (+0.28), CPN: 14.18 (+0.39), WLB: 9.69 (+0.54), EPZM: 10.44 (-0.28), EIX: 73.99 (+0.15)
Epizyme Teams Up with Roche's Genentech for Tazemetostat
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:32AM CDT
Epizyme (EPZM) announced that it has entered into a collaboration agreement with Roche's (RHHBY) Genentech to evaluate tazemetostat, in combination Tecentriq.
ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), EPZM: 10.44 (-0.28)
Epizyme Initiates Collaboration on Combination Trial of Tazemetostat and Tecentriq(TM) (atezolizumab) for Treatment of Non-Hodgkin Lymphoma
BusinessWire - Wed Jun 22, 11:09AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today it has entered into a collaboration agreement with Genentech, a member of the Roche Group, to conduct a clinical trial to investigate the anti-cancer effects of Epizyme's EZH2 inhibitor, tazemetostat, and Genentech's recently approved anti-PD-L1 cancer immunotherapy, Tecentriq(TM) (atezolizumab), when used in combination. The study will evaluate this combination regimen for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
EPZM: 10.44 (-0.28)
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 2:05PM CDT
Epizyme, Inc. (EPZM) reported encouraging preliminary data from its ongoing, global phase II trial on lead pipeline candidate, tazemetostat, at the American Society of Hematology Meeting on Lymphoma Biology.
ABT: 39.63 (+0.89), PFE: 34.59 (+0.12), EPZM: 10.44 (-0.28), BMY: 72.64 (+0.33)
Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting
BusinessWire - Sun Jun 19, 6:53AM CDT
--Four of five cohorts have now surpassed futility, including follicular lymphoma with EZH2 mutation; responses observed in all patient cohorts
EPZM: 10.44 (-0.28)
Earnings Estimates Moving Higher for Epizyme (EPZM): Time to Buy?
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:56AM CDT
Epizyme (EPZM) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
EPZM: 10.44 (-0.28)
Ardelyx Appoints Robert Bazemore to Its Board of Directors
PR Newswire - Tue Jun 07, 8:00AM CDT
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Robert Bazemore joined the Company's Board of Directors. Mr. Bazemore, who currently serves as President and Chief Executive Officer of Epizyme, Inc., brings with him broad experience in drug development and in navigating the challenges associated with preparing growing organizations for commercialization. Following the appointment of Mr. Bazemore to its Board of Directors, Ardelyx will have six independent board members.
EPZM: 10.44 (-0.28), ARDX: 8.27 (+0.39)
Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
Ekta Bagri - Zacks Investment Research - Tue May 10, 1:29PM CDT
Epizyme, Inc. (EPZM) reported a loss of 41 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 47 cents and the year-ago loss of $1.75.
SHPG: 180.29 (+4.91), EPZM: 10.44 (-0.28), GSK: 42.56 (+0.80), CELG: 100.66 (+1.43)
Epizyme (EPZM) Posts Narrower-Than-Expected Loss in Q1
Ekta Bagri - Zacks Investment Research - Mon May 09, 9:15AM CDT
Epizyme posted narrower-than-expected loss in the first quarter of 2016.
EPZM: 10.44 (-0.28)
Epizyme reports 1Q loss
Automated Insights - Mon May 09, 5:46AM CDT
CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Monday reported a loss of $22.9 million in its first quarter.
EPZM: 10.44 (-0.28)
Epizyme Announces First Quarter 2016 Financial Results and Provides Update on Execution Against Multi-Year Company Vision
BusinessWire - Mon May 09, 5:40AM CDT
--Conference call to be held today at 8:00 a.m. Eastern Time
EPZM: 10.44 (-0.28)
Epizyme Announces Collaboration with Lymphoma Study Association to Evaluate Combination of Tazemetostat with R-CHOP in Front-line Non-Hodgkin Lymphoma
BusinessWire - Mon May 09, 5:35AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has entered into a collaboration agreement with the Lymphoma Study Association (LYSA) to investigate the combination of tazemetostat with R-CHOP as a front-line treatment in patients with diffuse large B-cell lymphoma (DLBCL). LYSA is a premier cooperative group in France dedicated to clinical and translational research for lymphoma, and is certified by the French National Cancer Institute. Under the agreement, the phase 1b/2 trial will be jointly conducted with the Lymphoma Academic Research Organisation (LYSARC), the operational arm of LYSA.
EPZM: 10.44 (-0.28)
Epizyme Continues to Build Senior Leadership Team with Appointment of Matthew Ros as Chief Operating Officer
BusinessWire - Fri May 06, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as Chief Operating Officer. In this role, Mr. Ros will be responsible for directing and operationalizing Epizyme's launch readiness efforts for tazemetostat, and will report to Epizyme's President and Chief Executive Officer, Robert Bazemore.
EPZM: 10.44 (-0.28)
Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Mesothelioma
BusinessWire - Wed May 04, 5:35AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for tazemetostat for the treatment of adults with mesothelioma characterized by BAP1 loss-of-function. In the third quarter of this year, the company plans to initiate a phase 2 study in patients with mesothelioma.
EPZM: 10.44 (-0.28)
Epizyme to Report First Quarter 2016 Financial Results and Provide Corporate Update on May 9, 2016 and to Participate in Upcoming May Conferences
BusinessWire - Mon May 02, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today that management will host a conference call and live audio webcast on Monday, May 9, 2016, at 8:00 a.m. Eastern Time to report first quarter 2016 financial results and provide a corporate update. In addition, the company will be participating in two investor conferences in the month of May, Bank of America Merrill Lynch 2016 Health Care Conference and the UBS Global Health Care Conference.
EPZM: 10.44 (-0.28)
Epizyme Broadens Executive Leadership Team with Experienced New Officer and Senior Management
BusinessWire - Mon Apr 25, 7:00AM CDT
--Jeannie Chu joined as Vice President of Program and Portfolio Management
EPZM: 10.44 (-0.28)
Epizyme (EPZM) Q1 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 5:57PM CDT
Epizyme, Inc. (EPZM) is expected to report first-quarter 2016 results on Apr 26.
GILD: 83.37 (+0.92), EPZM: 10.44 (-0.28), SNY: 41.19 (+0.90), CELG: 100.66 (+1.43)
Epizyme Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer Research Annual Meeting 2016
BusinessWire - Mon Apr 18, 8:01AM CDT
--Data demonstrate that tazemetostat is only a weak inducer of CYP3A-mediated metabolism
EPZM: 10.44 (-0.28)
The Zacks Analyst Blog Highlights: CEMEX S.A.B. de C.V., Westmoreland Coal, Calpine, Epizyme and Edison International
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 8:30AM CDT
The Zacks Analyst Blog Highlights: CEMEX S.A.B. de C.V., Westmoreland Coal, Calpine, Epizyme and Edison International
CX: 6.80 (+0.28), CPN: 14.18 (+0.39), WLB: 9.69 (+0.54), EPZM: 10.44 (-0.28), EIX: 73.99 (+0.15)
Potential Winners: 3 Small-Cap Stocks Surging this Week
Zacks Premium Research - Zacks Investment Research - Wed Apr 06, 1:59PM CDT
These companies' shares are up by over 10% in the last week, so you may not want to miss out on what these corporations have to offer.
PRMW: 10.89 (+0.16), VTAE: 10.54 (+0.15), EPZM: 10.44 (-0.28)
5 Top-Ranked Stocks to Buy Before Earnings Release in April
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:22AM CDT
In spite of all the hiccups in Q1, we have cherry picked stocks with the help of our screening methodology that have been able to bear the turmoil.
CX: 6.80 (+0.28), CPN: 14.18 (+0.39), WLB: 9.69 (+0.54), EPZM: 10.44 (-0.28), EIX: 73.99 (+0.15)
